Use of methylnaltrexone and related compounds
US6608075B2 · kind B2 · utility
61Cited by
29References
38Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 21, 2001 |
| Grant date | Aug 19, 2003 |
| Priority date | — |
| Expiry date | May 21, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for preventing or treating opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.